COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,785 Articles (22,523 medRxiv, 8,262 bioRxiv)

Most recent first Previous |  Page 1786: Articles 17851-17860  | Next

Exaggerated cytokine production in human peripheral blood mononuclear cells by recombinant SARS-CoV-2 spike glycoprotein S1 and its inhibition by dexamethasone
Olajide, O. A., Iwuanyanwu, V. U., Lepiarz-Raba, I., Al-Hindawi, A. A.
10.1101/2021.02.03.429536 — Posted: 2021-02-03
Variation in predicted COVID-19 risk among lemurs and lorises
Melin, A. D., Orkin, J. D., Janiak, M. C., Valenzuela, A., Kuderna, L. F., Marrone, F., Ramangason, H., Horvath, J. E., Roos, C., Kitchener, A. C., Khor, C. C., Lim, W. K., Lee, J. G., Tan, P., Umapathy, G., Raveendran, M., Harris, R. A., Gut, I., Gut, M., Lizano, E., Nadler, T., Zinner, D., Johnson, S. E., Jarvis, E. D., Fedrigo, O., Wu, D., Zhang, G., Farh, K. K.-H., Rogers, J., Marques-Bonet, T., Navarro, A., Juan, D., Arora, P. S., Higham, J. P.
10.1101/2021.02.03.429540 — Posted: 2021-02-03
Molecular dynamics simulation study of effects of key mutations in SARS-CoV-2 on protein structures
Lon, J. R., Xi, B., Zhong, B., Zheng, Y., Guo, P., Chen, Z., Du, H.
10.1101/2021.02.03.429495 — Posted: 2021-02-03
Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2
Dwivedy, A., Mariadasse, R., Ahmad, M., Chakraborty, S., Kar, D., Tiwari, S., Majumdar, T., Jeyakanthan, J., Biswal, B.
10.1101/2021.02.03.429510 — Posted: 2021-02-03
A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex
Khalili Yazdi, A., Li, F., Devkota, K., Perveen, S., Ghiabi, P., Hajian, T., Bolotokova, A., Vedadi, M.
10.1101/2021.02.03.429625 — Posted: 2021-02-03
Multi-specific DARPin(R) therapeutics demonstrate very high potency against mutated SARS-CoV-2 variants in vitro
Rothenberger, S., Walser, M., Malvezzi, F., Mayor, J., Ryter, S., Moreno, H., Liechti, N., Halg, S., Bosshart, A., Iss, C., Calabro, V., Cornelius, A., Hospodarsch, T., Neculcea, A., Looser, T., Mangold, S., Reichen, C., Radom, F., Dawson, K. M., Lewis, S., Steiner, D., Amstutz, P., Engler, O., Stumpp, M. T.
10.1101/2021.02.03.429164 — Posted: 2021-02-03
Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Pedro Galao, R., Jose Lista, M., Jimenez-Guardeno, J. M., Laing, A. G., Wu, Y., Joseph, M., Muir, L., Ng, W. M., Duyvesteyn, H. M. E., Zhao, Y., Bowden, T. A., Shankar-Hari, M., Rosa, A., Cherepanov, P., McCoy, L. E., Hayday, A. C., Neil, S. J. D., Malim, M. H., Doores, K. J.
10.1101/2021.02.03.429355 — Posted: 2021-02-03
Potential global impact of the N501Y mutation on MHC-II presentation and immune escape
Castro, A., Carter, H., Zanetti, M.
10.1101/2021.02.02.429431 — Posted: 2021-02-03
Full Brain and Lung Prophylaxis against SARS-CoV-2 by Intranasal Lentiviral Vaccination in a New hACE2 Transgenic Mouse Model or Golden Hamsters
Ku, M.-W., Authie, P., Bourgine, M., Anna, F., Noirat, A., Moncoq, F., Vesin, B., Nevo, F., Lopez, J., Souque, P., Blanc, C., Chardenoux, S., Lafosse, I., Hardy, D., Nemirov, K., Guinet, F., Langa Vives, F., Majlessi, L., Charneau, P.
10.1101/2021.02.03.429211 — Posted: 2021-02-03
Identification of the SHREK family of proteins as broad-spectrum host antiviral factors
Dabbagh, D., He, S., Hetrick, B., Chilin, L., Andalibi, A., Wu, Y.
10.1101/2021.02.02.429469 — Posted: 2021-02-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).